ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer and the chemotherapies such as gemcitabine/nab-paclitaxel are confronted with intrinsic or acquired resistance. The aim of this s...

Source: Journal of Experimental and Clinical Cancer Research - January 2, 2024 Category: Cancer & Oncology Authors: Cecilia Bergonzini, Alessandro Gregori, Tessa M. S. Hagens, Vera E. van der Noord, Bob van de Water, Annelien J. M. Zweemer, Bircan Coban, Mjriam Capula, Giulia Mantini, Asia Botto, Francesco Finamore, Ingrid Garajova, Liam A. McDonnell, Thomas Schmidt, E Tags: Research Source Type: research